Physician profile
Mitchell B Ohara
NPI 1285705004
$4,131.30
in general payments reported to CMS, 2019-2025
38 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $447 · 2021: $602 · 2022: $571 · 2023: $202 · 2024: $482 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $598.01 | 2019-2022 | |
| Abbott Laboratories | $484.37 | 2019-2024 | Coroflow, Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $415.94 | 2019-2024 | |
| Amgen INC. | $234.87 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.91 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $211.30 | 2021-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $187.77 | 2022-2024 | Camzyos |
| Boston Scientific Corporation | $178.75 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $155.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $150.42 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $138.27 | 2019-2023 | |
| Pfizer INC. | $122.81 | 2021-2025 | |
| Esperion Therapeutics, INC. | $118.98 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $105.18 | 2024 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $87.25 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Ohara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.